3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

J.R.Hecht; T.Trarbach; E.Jaeger; J.Hainsworth; R.A.Wolff; K.Lloyd; G.Bodoky; M.Borner; D.Laurent; C.Jacques

首页> 外文期刊>European Journal of Cancer Supplements >3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

【24h】

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

机译：3010口服CONFIRM 1（CF1）的最终总体生存期（OS）结果，这是一项接受奥沙利铂一线化疗的结肠或直肠转移性腺癌（mCRC）患者的随机，双盲，安慰剂对照III期临床试验-氟尿嘧啶/白细胞素（FOLFOX 4）和PTK787 / ZK 222584（PTK / ZK）或安慰剂（PBO）

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
J.R.Hecht; T.Trarbach; E.Jaeger; J.Hainsworth; R.A.Wolff; K.Lloyd; G.Bodoky; M.Borner; D.Laurent; C.Jacques;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. [J] . Hecht JR, Trarbach T, Hainsworth JD, Journal of Clinical Oncology . 2011,第15期

机译：转移性结直肠腺癌患者基于一线奥沙利铂的化学疗法加上口服血管内皮生长因子受体抑制剂PTK787 / ZK 222584的随机，安慰剂对照III期研究。
2. Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma. [J] . Van Cutsem E, Bajetta E, Valle J, Journal of Clinical Oncology . 2011,第15期

机译：含或不含PTK787 / ZK 222584的奥沙利铂，氟尿嘧啶和白叶素的随机，安慰剂对照III期研究在先前治疗过的转移性结直肠腺癌患者中的应用。
3. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. [J] . Thomas A, Trarbach T, Bartel C, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第4期

机译：IB期开放标签剂量递增研究对晚期大肠癌患者的口服血管生成抑制剂PTK787 / ZK 222584（PTK / ZK）联合FOLFOX4化疗。
4. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials [O] . A Giatromanolaki, M I Koukourakis, E Sivridis, 2012

机译：在随机CONFIRM试验中接受vatalanib（PTK787 / ZK222584）治疗的大肠癌患者的血管密度分析
5. C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC) [O] . Gauler T.C., Besse B, Meric J.B., 2007

机译：C1-01：II期开放标签研究，旨在研究IIB期或IV期非小细胞肺癌（NSCLC）患者口服PTK787 / ZK 222584（PTK / ZK）作为二线单药治疗

著录项

引文网络

相似文献

相关主题

期刊订阅